Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment

[1]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[2]  C. Reid,et al.  Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. , 2019, Clinical lymphoma, myeloma & leukemia.

[3]  M. Dimopoulos,et al.  Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. , 2019, Blood.

[4]  J. Min,et al.  18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  Kihyun Kim,et al.  Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy , 2017, American journal of hematology.

[6]  M. Dimopoulos,et al.  Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit , 2017, Blood Cancer Journal.

[7]  Bart Barlogie,et al.  Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. , 2017, The Lancet. Oncology.

[8]  J. Cheong,et al.  Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen , 2016, BMC Cancer.

[9]  T. Werner,et al.  18F-FDG uptake and clearance in patients with compromised renal function , 2016, Nuclear medicine communications.

[10]  M. Osman,et al.  Impact of Renal Failure on F18-FDG PET/CT Scans , 2017, Front. Oncol..

[11]  M. Dimopoulos,et al.  Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma , 2015, Haematologica.

[12]  H. Goldschmidt,et al.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Dingli,et al.  Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma , 2014, Blood Cancer Journal.

[14]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  M. Kersten,et al.  Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial , 2014, Haematologica.

[16]  M. Dimopoulos,et al.  The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma , 2013, Leukemia.

[17]  A. Davenport,et al.  Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  M. Dimopoulos,et al.  The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function. , 2012 .

[19]  R. Fanin,et al.  Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. , 2011, Blood.

[20]  B. Barlogie,et al.  Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  B. Barlogie,et al.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. , 2009, Blood.

[22]  Tomio Inoue,et al.  FDG-PET of patients with suspected renal failure: standardized uptake values in normal tissues , 2007, Annals of nuclear medicine.

[23]  T. Economopoulos,et al.  Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance , 2007, Leukemia & lymphoma.

[24]  G. Morgan,et al.  Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Eknoyan,et al.  Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2005, Kidney international.

[26]  E. Montserrat,et al.  Patients with multiple myeloma requiring long‐term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases , 1995, British journal of haematology.

[27]  M. Dimopoulos,et al.  Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  R. Fanin,et al.  A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. , 2007, Haematologica.

[29]  Terry M Therneau,et al.  Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.